Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesions\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease) or other gastrointestinal conditions which increase the risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days prior to beginning study treatment
Patients with clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding are NOT eligible for participation; these may include (but are not limited to):\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding \r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease)\r\n* Other gastrointestinal conditions with increased risk of perforation
Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation \r\n* History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within  days prior to beginning study treatment\r\n* Clinically significant (> / teaspoon) hemoptysis or gastrointestinal hemorrhage in the past  months
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =<  days prior to randomization\r\n* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n** Malabsorption syndrome\r\n** Any prior major resection of the stomach or small bowel
Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  weeks prior to administration of first dose of study drug
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion(s) with risk of bleeding\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Any of the following conditions:\r\n* Active peptic ulcer disease\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease) or other gastrointestinal conditions which increase the risk of perforation\r\n* History of new abdominal fistula, gastrointestinal perforation or intra-abdominal abscess =<  days prior to registration; NOTE: enrollment of patients with chronic/canalized fistulous tracts (present for >  days) is allowed\r\n* Serious or non-healing wound, ulcer, or bone fracture\r\n* History of familial QTc prolongation syndrome
Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  weeks prior to administration of first dose of study drug
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding, including (but not limited to) active peptic ulcer disease, known intraluminal metastatic lesions with risk of bleeding, inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease) or other gastrointestinal (GI) conditions with increased risk of perforation, history of abdominal fistula or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: \r\n* Active peptic ulcer disease \r\n* Known intraluminal metastatic lesion/s with risk of bleeding \r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation \r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =<  days prior to registration\r\n* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n** Malabsorption syndrome\r\n** Major resection of the stomach or small bowel
Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesions\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease) or other gastrointestinal conditions which increase the risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days prior to beginning study treatment
Patients with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesions\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions which increase the risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), diverticulitis or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding
Patients with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:\r\n* Active peptic ulcer disease\r\n* Known gastrointestinal intraluminal metastatic lesions (gastrointestinal serosa metastatic lesions are permitted)\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease) or other gastrointestinal conditions with increased risk of perforation\r\n* Patients with clinical symptoms or signs of gastrointestinal obstruction and patients who require parenteral hydration and/or nutrition
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding, including (but not limited to) active peptic ulcer disease, known intraluminal metastatic lesions with risk of bleeding, inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease) or other gastrointestinal (GI) conditions with increased risk of perforation, history of abdominal fistula or intra-abdominal abscess within  days prior to beginning study treatment
Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other GI condition associated with increased risk of perforation
Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other Gastrointestinal conditions with increased risk of perforation; history of abdominal fistula, GI perforation, or intra-abdominal abscess within  weeks before beginning study treatment
Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding
Patients will be excluded if they have had a major resection of the bowel that could influence absorption, inflammatory bowel disease, or other gastrointestinal conditions with increased risk of perforation, history of abdominal fistula, gastrointestinal perforation within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: \r\n* Active peptic ulcer disease \r\n* Known intraluminal metastatic lesion/s with risk of bleeding \r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation \r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  weeks prior to administration of first dose of study drug
No clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding within  days prior to registration including, but not limited to: \r\n* Active peptic ulcer\r\n* Known endoluminal metastatic lesion(s) with history of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: active peptic ulcer disease, known intraluminal metastatic lesion/s with risk of bleeding, Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Patient must not have any clinically significant gastrointestinal abnormality that may increase the risk of gastrointestinal (GI) bleeding including, but not limited to, active peptic ulcer disease, known intraluminal metastatic lesions with risk of bleeding, inflammatory bowel disease (e.g., ulcerative colitis, Crohns disease), other GI conditions with increased risk of perforation, history of abdominal fistula or GI perforation or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation \r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to registration
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities which might interfere with oral dosing, including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel that could affect the absorption of study drug\r\n* Inflammatory bowel disease\r\n* Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including\r\n* Active peptic ulcer disease, not on a proton pump inhibitor\r\n* Known intraluminal metastatic lesions\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or \r\n* Other gastrointestinal conditions which increase the risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: \r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment\r\n* Clinically significant hemoptysis or gastrointestinal hemorrhage in the past  months
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal (GI) bleeding including, but not limited to: \r\n* Active peptic ulcer disease; \r\n* Known intraluminal metastatic lesion/s with suspected bleeding; \r\n* Inflammatory bowel disease; \r\n* Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation; \r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
EXPANSION COHORT ONLY: Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding including, but not limited to:\r\n* Activepeptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with suspected bleeding\r\n* Inflammatory bowel disease \r\n* Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation
Active peptic ulcer disease, inflammatory bowel disease (eg, ulcerative colitis, Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding.
Clinically significant gastrointestinal abnormalities including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel that could affect the absorption of study drug\r\n* Active peptic ulcer disease\r\n* Inflammatory bowel disease\r\n* Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: active peptic ulcer disease; known intraluminal metastatic lesion/s with risk of bleeding; inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within  days prior to beginning study treatment
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding (e.g. active peptic ulcer, ulcerative colitis, Crohns disease, abdominal fistula) within prior  months
No clinically significant gastrointestinal abnormalities that may increase the risk of gastrointestinal bleeding within  days prior to registration including, but not limited to:\r\n* Active peptic ulcer\r\n* Known endoluminal metastatic lesion(s) with history of bleeding\r\n* Active inflammatory bowel disease (e.g. ulcerative colitis, Crohns Disease), or other gastrointestinal conditions with increased risk of perforation
Patients must not have clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:\r\n* Active peptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with risk of bleeding \r\n* Inflammatory bowel disease (e.g. ulcerative colitis, Crohns disease), or other gastrointestinal conditions with increased risk of perforation\r\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment
